Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mupirocin-Iodophor ICU Decolonization Swap Out Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03140423
Recruitment Status : Recruiting
First Posted : May 4, 2017
Last Update Posted : August 6, 2018
Sponsor:
Collaborators:
Hospital Corporation of America
University of California, Irvine
University of Massachusetts, Amherst
Rush University
Centers for Disease Control and Prevention
Information provided by (Responsible Party):
Richard Platt, Harvard Pilgrim Health Care

Brief Summary:

The Swap Out Trial is a cluster randomized controlled trial of HCA hospitals, evaluating the non-inferiority of two decolonization regimens:

Arm 1 Routine Care: ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing; Arm 2 Intervention: ICU nasal decolonization with iodophor twice daily for 5 days in the context of chlorhexidine for daily bathing Note: that enrolled "subjects" represents 137 individual HCA Hospitals (representing ~235 ICUs) that have been randomized.


Condition or disease Intervention/treatment Phase
Staphylococcus Aureus Drug: Arm 1. Routine Care (Mupirocin/CHG) Drug: Arm 2. Iodophor/CHG Decolonization Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 137 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Non-inferiority cluster randomized controlled trial
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Cluster-randomized Non-inferiority Trial Comparing Mupirocin vs Iodophor for Nasal Decolonization of ICU Patients to Assess Impact on S. Aureus Clinical Cultures and All-cause Bloodstream Infection During Routine Chlorhexidine Bathing
Actual Study Start Date : May 1, 2017
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Arm 1: Routine Care (Mupirocin/CHG)
ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing
Drug: Arm 1. Routine Care (Mupirocin/CHG)
The intervention / decolonization regimen will consist of 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.

Active Comparator: Arm 2: Iodophor/CHG Decolonization
ICU nasal decolonization with iodophor twice daily for 5 days in the context of chlorhexidine for daily bathing
Drug: Arm 2. Iodophor/CHG Decolonization
The intervention / decolonization regimen will consist of 5 days of topical intranasal iodophor (10% povidone-iodine nasal swabs) (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.




Primary Outcome Measures :
  1. ICU-attributable S. aureus clinical cultures (MRSA + MSSA) [ Time Frame: 18-month intervention ]
    Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-susceptible Staphylococcus aureus (MSSA) clinical cultures attributable to participating ICUs. Defined as occurring >2 days into a participating ICU stay through 2 days following ICU discharge.


Secondary Outcome Measures :
  1. ICU attributable MRSA clinical cultures [ Time Frame: 18-month intervention ]
    Methicillin-resistant Staphylococcus aureus (MRSA) clinical cultures attributable to participating ICUs. Defined as occurring >2 days into a participating ICU stay through 2 days following ICU discharge.

  2. ICU-attributable all-cause bloodstream infection [ Time Frame: 18-month intervention ]
    All-cause bloodstream infection attributable to participating ICUs. Defined as occurring >2 days into a participating ICU stay through 2 days following ICU discharge.Includes subsets of gram positive (GP), gram negative (GN) and fungal (candida) bloodstream infections, as well as key pathogens such as S. aureus (MRSA and MSSA).

  3. Mupirocin resistance in MRSA isolates [ Time Frame: 18-month intervention ]
    Mupirocin resistance as measured by minimum inhibitory concentration (MIC) among MRSA isolates from ICU patients between arms

  4. Iodophor resistance in MRSA isolates [ Time Frame: 18-month intervention ]
    Iodophor resistance as measured by iodophor minimum inhibitory concentration (MIC) among MRSA isolates from ICU patients between arms



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Inclusion criteria includes all U.S. HCA hospitals with an adult ICU;
  • Note: Unit of randomization is the hospital, but the participants are hospital adult ICUs
  • All patients within adult ICUs are included, including rare patients <18 years and >=12 years.

Exclusion Criteria:

  • Exclusion criteria includes ICUs with an average length of stay of less than 2 days;
  • HCA hospitals that are not able to transfer or merge data into the centralized data warehouse for the baseline and intervention periods of the study are also excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03140423


Contacts
Layout table for location contacts
Contact: Katie Haffenreffer 617-867-4807 Katie_Haffenreffer@hphc.org
Contact: Susan Huang, MD, MPH sshuang@uci.edu

  Show 137 Study Locations
Sponsors and Collaborators
Harvard Pilgrim Health Care
Hospital Corporation of America
University of California, Irvine
University of Massachusetts, Amherst
Rush University
Centers for Disease Control and Prevention
Investigators
Layout table for investigator information
Principal Investigator: Richard Platt, MD, MS Harvard Pilgrim Health Care Institute
Study Director: Susan Huang, MD, MPH University of California, Irvine

Layout table for additonal information
Responsible Party: Richard Platt, Professor and Department Chair, Harvard Pilgrim Health Care
ClinicalTrials.gov Identifier: NCT03140423     History of Changes
Other Study ID Numbers: PH000599A
First Posted: May 4, 2017    Key Record Dates
Last Update Posted: August 6, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Richard Platt, Harvard Pilgrim Health Care:
MRSA
healthcare-associated infections
mupirocin
iodophor
resistance

Additional relevant MeSH terms:
Layout table for MeSH terms
Chlorhexidine
Chlorhexidine gluconate
Mupirocin
Anti-Infective Agents, Local
Anti-Infective Agents
Disinfectants
Dermatologic Agents
Anti-Bacterial Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action